AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 3, 2026 Denali Therapeutics reported Q3 2026 net income of $70.1 million and AVLAYAH net product revenue of $17.8 million. AI-generated summary · Source: company release
NASDAQ: $DNLIBiotech · Brain deliveryLaunch, confirmatory-trial and funding risk

DNLI Stock Hub: Denali Therapeutics News, AVLAYAH and TransportVehicle

Denali reported $17.778M in Q3 AVLAYAH net sales and forecast $30M–$32M for Q4. September cash and marketable securities totaled $1,007.572M. The $70.126M quarterly net profit included a one-time voucher-sale gain; AVLAYAH has accelerated approval, while confirmatory evidence and the wider pipeline remain important risks. Q3 2026 Form 10-Q · November 3 Q3 results and pipeline · November 3, 2026 AVLAYAH FDA prescribing information · March 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Denali: AVLAYAH Launch and the TransportVehicle Pipeline
A commercial launch, confirmatory evidence and new brain-delivery cargos · November 12, 2026
Get the report (PDF)
Next catalyst · Announced investor event
November 17, 2026 · UBS Global Biopharma Conference

Denali lists its UBS session at 14:40–15:10 GMT, equivalent to 09:40–10:10 in New York. This is a corporate presentation, without a promise of new clinical results. Denali investor event schedule · November 2026

The November 11 Stifel session is past. Next clinical window: zafinofusp Phase 1/2 data presentation at a medical congress in Q1 2027; its BLA submission remains planned for 2027. Denali investor event schedule · November 2026 Q3 results and pipeline · November 3, 2026
DNLI daily price chart
Daily chart · Finviz (affiliate link on click). Explore DNLI on JC Just Charts.

DNLI stock data: financial position and capital

REFERENCE CLOSE
$19.73
November 11 regular session
COMMON-STOCK VALUE
$3.163B
Calculated using October 28 common shares
CASH + MARKETABLES
$1,007.572M
September 30 · includes long-term securities
Q3 AVLAYAH SALES
$17.778M
Three months ended September 30
Q4 SALES GUIDANCE
$30M–$32M
Company forecast · not reported revenue
OPERATING CASH USED
$345.649M
Nine months ended September 30
ORDINARY SHARES
160.291M
October 28 · excludes 28.332M pre-funded
ROYALTY LIABILITY
$209.661M
September 30 · debt-financing accounting

Resources equal $102.870M cash and equivalents + $413.326M short-term securities + $491.376M long-term securities. The common-share count excludes 28,331,779 pre-funded warrants. Royalty participation is a financing obligation separate from ordinary equity; not a second amount to add to total liabilities. Q3 2026 Form 10-Q · November 3

DNLI stock: launch momentum and the quality of quarterly profit

The $70.126M Q3 profit included a $194M net gain from selling a Priority Review Voucher. Operations lost $126.751M, and nine-month operating cash flow remained negative. AVLAYAH approval is accelerated and continued approval may depend on confirmatory clinical benefit. Q3 2026 Form 10-Q · November 3 AVLAYAH FDA prescribing information · March 2026

▲ The constructive case

AVLAYAH gives Denali a commercial product and an example of transferrin-receptor brain delivery accepted for accelerated approval. Launch revenue, expanding reimbursement and multiple 2027 data windows can provide further evidence across the portfolio. Q3 results and pipeline · November 3, 2026 AVLAYAH FDA prescribing information · March 2026

▼ The cautious case

Single-product exposure, infusion and immune safety risks, confirmatory requirements and high development spending remain material. The LUMA failure illustrates the gap between a biological mechanism and clinical benefit; pre-funded warrants and employee awards expand economic exposure beyond ordinary shares. Q3 2026 Form 10-Q · November 3 Biogen and Denali LUMA results · May 21, 2026 AVLAYAH FDA prescribing information · March 2026

Latest DNLI news

Nov 3, 2026

Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

Denali reported Q3 2026 net income of $70.1 million, including a one-time $194.0 million net gain on the sale of a Priority Review Voucher. AVLAYAH net product revenue was $17.8 million in its second full commercial quarter, and Q4 2026 net product revenue is expected to be $30.0 million to $32.0 million. Cash, cash equivalents and marketable securities were approximately $1.0 billion as of September 30, 2026.

Company release · SEC

DNLI stock catalysts: AVLAYAH launch, zafinofusp and brain-delivery data

Registry primary-completion estimates differ from company disclosure windows. The AVLAYAH approval date was March 24, 2026; the announcement was March 25. LUMA results were reported May 21 and idiopathic Parkinson development was discontinued. FDA corrected approval letter · effective March 24, 2026 AVLAYAH approval announcement · March 25, 2026 Biogen and Denali LUMA results · May 21, 2026

AVLAYAH: sales, approved use and confirmatory evidence

AVLAYAH treats neurologic manifestations of Hunter syndrome when initiated in eligible pediatric patients weighing at least 5 kg before advanced neurologic impairment. It is not a general approval for all MPS disorders or the rest of the platform. AVLAYAH FDA prescribing information · March 2026

The label reports a 91% mean reduction in CSF heparan sulfate at week 24 among 44 patients with measurements; 41 of 44 were below the upper normal limit. These biomarker results supported accelerated approval. COMPASS has enrolled 65 across cohorts, with company-guided data in H1 2028. AVLAYAH FDA prescribing information · March 2026 Q3 results and pipeline · November 3, 2026

Q3 sales were $17.778M. Manufacturing costs expensed before approval make initial cost of goods unusually low; current margins are not a mature manufacturing run rate. Royalty Pharma receives a 9.25% participation in worldwide AVLAYAH sales subject to contractual caps. Q3 2026 Form 10-Q · November 3

TransportVehicle pipeline: zafinofusp, progranulin, tau and LRRK2

Zafinofusp targets MPS IIIA; its planned 2027 BLA is separate from AVLAYAH approval. DNL593 for FTD-GRN and DNL628 for Alzheimer’s disease have H1 2027 data windows. DNL921 and DNL952 target data in 2027. All remain investigational. Q3 results and pipeline · November 3, 2026

LUMA failed primary and secondary endpoints in early Parkinson’s disease. The independent BEACON Phase 2a study continues in carriers of pathogenic LRRK2 variants; it is a separate population and primarily a safety and pharmacodynamic study. Biogen and Denali LUMA results · May 21, 2026 NCT06602193 · trial registry

Zafinofusp’s earlier dose-finding observations used different populations: week-49 CSF HS data were available for seven patients, while the safety set comprised fourteen. All fourteen had infusion-related reactions and related treatment-emergent events; four had serious events considered unrelated. No grade 4/5 events, deaths or event-related early discontinuations were reported in that preliminary set. Denali corporate presentation · November 9, 2026

Merlintrader Health Score · DNLI

3.60out of 5
Financial position4.0

Cash and marketable securities totaled $1,007.572M at September 30, while nine-month operating cash use was $345.649M. Management expects existing resources to cover at least twelve months after the November 3 filing; Royalty Pharma participation reduces future retained sales. Q3 2026 Form 10-Q · November 3

Catalysts3.5

Q4 AVLAYAH revenue guidance is $30M–$32M. Zafinofusp data presentation is planned for Q1 2027 and a BLA for 2027; several early programs have 2027 data windows. These are forecasts, while COMPASS confirmatory data are expected in H1 2028. Q3 results and pipeline · November 3, 2026

Dilution3.0

September capital included 28,331,779 pre-funded warrants, 21,244,006 options and 6,535,718 unvested RSUs in addition to common stock. The $400M ATM had not been used. Not all potential securities are equivalent to shares already issued. Q3 2026 Form 10-Q · November 3

Trading liquidity4.0

DNLI common stock is listed on the Nasdaq Global Select Market and has an active daily trading history. The large gap between ordinary shares and economic exposure including pre-funded warrants makes denominator choice material; clinical or launch news can change execution conditions. Q3 2026 Form 10-Q · November 3

Execution3.5

Denali obtained accelerated AVLAYAH approval and reached $17.778M Q3 sales, while LUMA failed its endpoints and idiopathic Parkinson development was discontinued. Confirmatory clinical benefit and success of other TransportVehicle cargos remain outstanding development risks. Q3 2026 Form 10-Q · November 3 Q3 results and pipeline · November 3, 2026 Biogen and Denali LUMA results · May 21, 2026

Weighted calculation: 4.0 × 30% + 3.5 × 30% + 3.0 × 20% + 4.0 × 10% + 3.5 × 10% = 3.60 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of clinical success.

DNLI red flags

DNLI Stock FAQ: Denali Questions Answered

When is the next DNLI stock catalyst?

As of November 12, 2026, Denali’s next scheduled corporate presentation is UBS on November 17 at 14:40 GMT, or 09:40 New York. No new clinical results were promised for that event. The next clinical presentation window is zafinofusp in Q1 2027, while its BLA remains planned for 2027. Denali investor event schedule · November 2026 Q3 results and pipeline · November 3, 2026

Is Denali AVLAYAH FDA approved?

AVLAYAH has FDA accelerated approval effective March 24, 2026, for eligible pediatric patients with neurologic manifestations of Hunter syndrome. Treatment must begin at a weight of at least 5 kg before advanced neurologic impairment. The announcement followed March 25; continued approval may require confirmation of clinical benefit. Other Denali candidates remain investigational. FDA corrected approval letter · effective March 24, 2026 AVLAYAH FDA prescribing information · March 2026 Q3 results and pipeline · November 3, 2026

How much cash does Denali have?

September 30, 2026 cash and equivalents were $102.870 million, with $413.326 million short-term and $491.376 million long-term marketable securities, totaling $1,007.572 million. Nine-month operating cash use was $345.649 million. The company expects resources to fund at least twelve months after the November 3, 2026 filing under its assumptions. Q3 2026 Form 10-Q · November 3

Can DNLI stock face share dilution?

The October 28, 2026 cover count of 160,290,546 common shares excludes 28,331,779 pre-funded warrants. September 2026 options totaled 21,244,006 and unvested RSUs 6,535,718. Denali also had an unused $400 million ATM. Exercise, vesting and future issuance can change the denominator, while potential securities differ from shares already outstanding. Q3 2026 Form 10-Q · November 3

When did Denali report Q3 earnings?

Denali reported on November 3, 2026. Q3 AVLAYAH revenue was $17.778 million and net income $70.126 million. A $194 million voucher-sale net gain supported the profit, while the operating result was a $126.751 million loss. Q4 revenue guidance is $30 million to $32 million, a forecast. Q3 2026 Form 10-Q · November 3 Q3 results and pipeline · November 3, 2026

What does Denali Therapeutics do?

As of November 12, 2026, Denali develops medicines for neurodegenerative and lysosomal storage diseases, including therapies engineered to cross the blood-brain barrier. Its TransportVehicle platform carries different therapeutic cargos. AVLAYAH is commercially available for its approved Hunter syndrome population; zafinofusp and the other pipeline candidates remain experimental. Q3 2026 Form 10-Q · November 3 Q3 results and pipeline · November 3, 2026

What is Denali COMPASS testing?

As of November 12, 2026, Denali is running COMPASS, the randomized, active-controlled Phase 2/3 study of tividenofusp alfa versus idursulfase. The registry identifies biomarker and adaptive-behavior endpoints for Cohort A. Denali reported 65 participants enrolled across Cohorts A and B and expects data in H1 2028. NCT05371613 · trial registry Q3 results and pipeline · November 3, 2026

What happened in Denali LUMA and BEACON?

Biogen and Denali reported May 21, 2026 that LUMA failed its primary and secondary endpoints in early Parkinson’s disease, and idiopathic Parkinson development was discontinued. Denali continues BEACON in carriers of pathogenic LRRK2 variants. BEACON has a different population and a safety primary endpoint, with company-guided data in H1 2027. Biogen and Denali LUMA results · May 21, 2026 NCT06602193 · trial registry Q3 results and pipeline · November 3, 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $DNLI or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models